Sofinnova Partners, a European life sciences venture capital firm, completed the investment in Genespire, a Milan-based gene-therapy company. Financial terms were not disclosed. "These investments are the result of the excellent collaboration between Sofinnova Partners and The Telethon Foundation. These exceptional start-up companies validate our conviction in the strength of the Italian market for supporting biotechnological advances," Graziano Seghezzi, Sofinnova Partners Managing Partner.